Compare iShares Core High Dividend ETF (HDV) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Heron Therapeutics Inc — how do they compare? iShares Core High Dividend ETF trades at $28.15, while Heron Therapeutics Inc trades at $0.47 (market cap $91.46M). The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HDV | HRTX | |
|---|---|---|
52-Week High | $28.36 | $1.96 |
52-Week Low | $23.64 | $0.39 |
Market Cap | — | $91.46M |
Sector | — | Health |
Enterprise Value | — | $189.36M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $28.18, down 0.25% on the day, with a bullish technical signal driven by moving averages. The ETF maintains a 3.0% dividend yield, with recent payouts of $0.19 and $0.09 per share. News coverage highlights HDV's defensive sector focus and competitive expense ratio compared to peers like SCHD and VYM, though some analysts note concentration risk in energy holdings.
Outlook remains cautiously positive given HDV's low volatility and income appeal, but investors face risks from oil price sensitivity and modest dividend growth. The ETF's quality screen provides stability, yet sector concentration may limit upside if energy underperforms.
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
